Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
Wiviott, Stephen D × Braunwald, Eugene McCabe, Carolyn H Horvath, Ivan Keltai, Matyas Herrman, Jean-Paul R Van de Werf, Frans Downey, William E Scirica, Benjamin M Murphy, Sabina A Antman, Elliott M #
Elsevier science inc
Lancet vol:371 issue:9621 pages:1353-1363
Background Intracoronary stenting can improve procedural success and reduce restenosis compared with balloon angioplasty in patients with acute coronary syndromes, but can also increase the rate of thrombotic complications including stent thrombosis. The TRITON-TIMI 38 trial has shown that prasugrel-a novel, potent thienopyridine-can reduce ischaemic events compared with standard clopidogrel therapy. We assessed the rate, outcomes, and prevention of ischaemic events in patients treated with prasugrel or clopidogrel with stents in the TRITON-TIMI 38 study.